U.S. markets closed

Applied Molecular Transport Inc. (AMTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0200+0.0903 (+9.71%)
At close: 01:00PM EST
1.0100 -0.01 (-0.98%)
After hours: 04:47PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.9297
Bid0.8500 x 1200
Ask1.0400 x 800
Day's Range0.9000 - 1.0300
52 Week Range0.8030 - 17.9100
Avg. Volume150,785
Market Cap39.722M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-3.1840
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AMTI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Applied Molecular Transport Inc
    Daily – Vickers Top Buyers & Sellers for 07/07/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

    SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, which is also in development for the treat

  • GlobeNewswire

    Applied Molecular Transport to Present at Upcoming November Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences: Event: Guggenheim 4th Annual Immunology and Neurology DayFormat: Corporate Presentation Date & Time: Monday, November 14, 2022, at 9:35 a.m. ET Location: New York, New YorkPresenter: Tahir Mahmood, Ph.D., chief executive officer and co-founder Event: Jefferies Lond

  • GlobeNewswire

    Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2 top-line readout for oral AMT-101 in UC monotherapy in late 2022 or early 2023, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate upd